{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-283861","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2025-11-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.046696+00:00","generated_at":"2026-05-16T19:16:54.047680+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"4D Molecular Therapeutics appoints Kristian Humer as CFO effective Nov 17, 2025","bullets":["Kristian Humer, formerly CFO at Foghorn Therapeutics and Viridian Therapeutics, joins as CFO and Principal Financial Officer.","Compensation includes $520K base salary, 40% target bonus, option for 480K shares, and $100K sign-on bonus paid in two installments.","Severance: 9 months base salary + COBRA if terminated w/o cause or for good reason; 12 months + COBRA plus full equity acceleration if within 12 months of a change in control."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-283861","json":"https://secwatch.observer/filing/0001193125-25-283861.json","markdown":"https://secwatch.observer/filing/0001193125-25-283861.md","text":"https://secwatch.observer/filing/0001193125-25-283861.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000119312525283861/0001193125-25-283861-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000119312525283861/d14139d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:16:54.047680+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}